Key Objective
Initial public offering of 19,189,330 equity shares of face value of Rs. 2 each of Suraksha Diagnostic Limited (the "Company" or the "Issuer") for cash at a price of Rs. 441 per equity share (including a premium of Rs. 439 per equity share) (the "Offer Price") aggregating to Rs. 846.25 crores through an offer for sale of 19,189,330 equity shares of face value of Rs. 2 each aggregating to Rs. 846.25 crores, comprising 2,132,148 equity shares of face value of Rs. 2 each aggregating to Rs. 94.03 crores by Somnath Chatterjee, 2,132,148 equity shares of face value of Rs. 2 each aggregating to Rs. 94.03 crores by Ritu Mittal, 2,132,148 equity shares of face value of Rs. 2 each aggregating to Rs. 94.03 crores by Satish Kumar Verma (whose shares are jointly held with Suman Verma) (together with Somnath Chatterjee and Ritu Mittal, the "Promoter Selling Shareholders"), 10,660,737 equity shares of face value of Rs. 2 each aggregating to Rs. 470.14 crores by Orbimed Asia ii Mauritius Limited^ (the "Investor Selling Shareholder"), 799,556 equity shares of face value of Rs. 2 each aggregating to Rs. 35.26 cores by Munna Lal Kejriwal, and 1,332,593 equity shares of face value of Rs. 2 each aggregating to Rs. 58.77 crores by Santosh Kumar Kejriwal (together the "Individual Selling Shareholders") (the promoter selling shareholders, the investor selling shareholder and the individual selling shareholders, collectively referred to as the "Selling Shareholders", and such equity shares offered by the selling shareholders, the "Offered Shares") (the "Offer" or the "Offer for Sale"). The offer constitutes 36.84% of the post-offer paid-up equity share capital of the company.
^ Surviving entity pursuant to amalgamation of orbimed Asia ii Mauritius fdi investments limited, the erstwhile shareholder, into orbimed asia ii mauritius limited on november 11, 2022
The face value of the equity shares is Rs. 2 each and the offer price is 220.5 times the face value of the equity shares.